CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.
  
  LEARNING OBJECTIVES

  • Assess the anticipated benefits, risks and long-term outcomes associated with the use of adjuvant and neoadjuvant therapy in the management of Stage IB-IIIA non-small cell lung cancer (NSCLC), and consider this information when counseling individuals regarding current therapeutic recommendations.
  • Recognize the prevalence of EGFR alterations found in patients with localized NSCLC, and refine diagnostic algorithms in your practice to ensure more accurate identification of individuals harboring these genetic abnormalities.
  • Appreciate recently presented Phase III findings supporting the efficacy of adjuvant osimertinib for patients with EGFR mutation-positive NSCLC after complete resection, and consider the potential effect of this information on current and future clinical practice.
  • Evaluate the tolerability and toxicity of osimertinib for patients with early-stage NSCLC, and understand the benefit/risk ratio associated with long-term treatment with an EGFR inhibitor in the curative setting.
  • Recall ongoing clinical trials evaluating EGFR-directed therapies for patients with localized NSCLC, and counsel appropriate individuals about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and his spouse/partner) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Roy S Herbst, MD, PhD
  Ensign Professor of Medicine (Medical Oncology)
  Professor of Pharmacology
  Chief of Medical Oncology
  Yale Cancer Center and Smilow Cancer Hospital
  Associate Cancer Center Director, Translational Science
  New Haven, Connecticut
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, BioNTech AG, Bolt Biotherapeutics, Candel Therapeutics, Cybrexa Therapeutics, EMD Serono Inc, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals Inc, Novartis, Ribon Therapeutics, STCube; Consulting Agreements: AbbVie Inc, ARMO Biosciences, a wholly owned subsidiary of Eli Lilly and Company, AstraZeneca Pharmaceuticals LP, Biodesix Inc, BioNTech AG, Bolt Biotherapeutics, Bristol-Myers Squibb Company, Candel Therapeutics, Cybrexa Therapeutics, eFFECTOR Therapeutics Inc, EMD Serono Inc, Forte Biosciences Inc, Genentech, a member of the Roche Group, Genmab, Halozyme Inc, Heat Biologics Inc, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mirati Therapeutics, Nektar, NextCure, Novartis, Oncternal Therapeutics, Pfizer Inc, Ribon Therapeutics, Sanofi Genzyme, Seagen Inc, Spectrum Pharmaceuticals Inc, STCube, Symphogen A/S, Takeda Oncology, Tesaro, A GSK Company, WindMIL Therapeutics, Xencor; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Lilly, Merck; Data and Safety Monitoring Board/Committee: EMD Serono Inc, Novartis; Nonexecutive Directorship: Immunocore Holdings Limited, Junshi Biosciences (Independent).
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.
  
  Release date: April 2021
  Expiration date: April 2022